These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17607934)

  • 1. Tyrosine kinase inhibitors and cancer therapy.
    Madhusudan S; Ganesan TS
    Recent Results Cancer Res; 2007; 172():25-44. PubMed ID: 17607934
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine kinases as targets for cancer therapy.
    Krause DS; Van Etten RA
    N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
    [No Abstract]   [Full Text] [Related]  

  • 3. Bad patients meet good drugs.
    Lacal JC
    Clin Transl Oncol; 2006 Apr; 8(4):225-7. PubMed ID: 16648096
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel tyrosine kinase inhibitors in the treatment of cancer.
    Ocana A; Serrano R; Calero R; Pandiella A
    Curr Drug Targets; 2009 Jun; 10(6):575-6. PubMed ID: 19519359
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 6. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
    Cepero V; Sierra JR; Giordano S
    Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H
    Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract]   [Full Text] [Related]  

  • 10. Meeting report: targeting the kinome--20 years of tyrosine kinase inhibitor research in Basel.
    Bozulic L; Morin P; Hunter T; Hemmings BA
    Sci STKE; 2007 Feb; 2007(374):pe8. PubMed ID: 17317657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heritable resistance to tyrosine kinase inhibitors.
    Ong ST
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):454-7. PubMed ID: 25322326
    [No Abstract]   [Full Text] [Related]  

  • 13. [Kinase inhibitors].
    Yamori T; Kong D
    Nihon Rinsho; 2010 Jun; 68(6):1059-66. PubMed ID: 20535956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.
    Fauvel B; Yasri A
    MAbs; 2014; 6(4):838-51. PubMed ID: 24859229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.
    Thirumal Raj A; Patil S; Ranadheer R; Chandini R
    Oral Oncol; 2017 Oct; 73():172. PubMed ID: 28923250
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
    Mross K
    Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
    [No Abstract]   [Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors in cancer therapy.
    Eckhardt S
    Anticancer Agents Med Chem; 2008 Jun; 8(5):461. PubMed ID: 18537528
    [No Abstract]   [Full Text] [Related]  

  • 19. Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models.
    Crespan E; Zucca E; Maga G
    Curr Med Chem; 2011; 18(19):2836-47. PubMed ID: 21651495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors in pediatric malignancies.
    Skolnik JM; Adamson PC
    Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.